Navigation Links
Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
Date:5/11/2009

lopment expenses, which totaled $42.6 million in the first quarter of 2009, declined from $47.4 million in the first quarter of 2008. This decrease in research and development expenses is primarily attributable to decreased clinical trial costs due to the completion of clinical and preclinical studies as Arena prioritized its spending towards the completion of trials for lorcaserin. Research and development expenses are expected to continue to significantly decline throughout the year as the lorcaserin pivotal Phase 3 studies complete. Research and development expenses included $0.9 million in non-cash, share-based compensation expense in the quarter ended March 31, 2009, compared to $1.0 million in the quarter ended March 31, 2008. General and administrative expenses totaled $7.6 million in the first quarter of 2009, compared to $8.9 million in the first quarter of 2008. This decrease in general and administrative expenses is primarily attributable to decreased patent costs. General and administrative expenses in the first quarter of 2009 included $1.1 million in non-cash, share-based compensation expense, compared to $1.4 million in the first quarter of 2008.

At March 31, 2009, cash, cash equivalents and short-term investments totaled $70.3 million and approximately 74.3 million shares of common stock were outstanding.

In April 2009, Arena received aggregate net proceeds of $14.6 million from the sale of approximately 5.7 million shares under a $50.0 million equity financing commitment entered into in March 2009 with Azimuth Opportunity Ltd., or Azimuth.

Arena's First Quarter and Recent Developments

  • Abstract accepted for presentation of data from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management, at the 69th Scientific Sessions of t
    '/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
2. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
3. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
4. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
5. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
6. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
7. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
8. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
9. Arena Pharmaceuticals Announces Second Quarter 2008 Financial Results and Recent and Second Quarter Highlights
10. Arena Pharmaceuticals to Report Second Quarter 2008 Financial Results and to Host Conference Call and Webcast on Tuesday, August 5, 2008
11. Arena Pharmaceuticals to Present at the Seventh Annual Needham & Company, LLC Biotechnology and Medical Technology Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... 27, 2015 Junto Health, a company that ... and develop new technology solutions, today announced the launch ... a leader in health care policy consulting. Working together ... a collaborative innovation process while, at the same time, ... public policy, health care finance and the delivery of ...
(Date:7/24/2015)... , July 24, 2015 Ryan & Maniskas, ... in United States District Court for the Northern District of ... or entities that purchased the common stock of Avalanche Biotechnologies, ... July 31, 2014 and June 15, 2015, inclusive (the "Class ... 8, 2015, move the Court for appointment as a lead ...
(Date:7/24/2015)... Agritech Limited (NASDAQ GS: SEED) ("Origin", or the "Company"), a ... , today announced that the Company will report results for ... before the market opens on Wednesday, August 5th, 2015. ... 2015, at 9:00 a.m. ET / 9:00 p.m. ... in the call, please dial the following numbers approximately 5 ...
(Date:7/23/2015)... ... ... The health and wellness of brain tumor caregivers, often a spouse, parent, sibling ... American Brain Tumor Association presents interactive sessions that address shifting the mindset of caregivers ... Chicago. , “We have understood for a long-time now that caregivers and families ...
Breaking Biology Technology:Junto Health Announces a Unique Partnership with Sachs Policy Group 2Junto Health Announces a Unique Partnership with Sachs Policy Group 3Junto Health Announces a Unique Partnership with Sachs Policy Group 4Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 2Ryan & Maniskas, LLP Announces Class Action Lawsuit Against Avalanche Biotechnologies, Inc. 3Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 2Origin Agritech Limited to Announce Third Quarter Fiscal 2015 Unaudited Financial Results on August 5th, 2015 3Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 2Reframing the Caregiver and Patient Mindset: Coping with the ‘New Normal’ 3
... -- LEUVEN, Belgium, September 30, 2010 ... ... ... are keyed by longUrl, so we need to grab the first one. for (var r in data.results) ...
... While refining their novel method for making nanoscale ... and Technology (NIST) discovered an unexpected bonusa new ... to that from light-emitting diodes (LEDs). These "nano-LEDs" ... to work serving miniature devices such as nanogenerators ...
... Sept. 29 /PRNewswire-FirstCall/ - Generex Biotechnology Corporation (Nasdaq: ... development, and commercialization of drug delivery systems and technologies, ... Mark Fletcher as Interim President and Chief Executive Officer ... an independent director, to serve as Chairman of the ...
Cached Biology Technology:ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 2ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 3ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 4ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 5ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 6ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 7ThromboGenics Signs Deal With MSD for Long-Term Commercial Supply of Microplasmin 8Growing nanowires horizontally yields new benefit: 'nano-LEDs' 2Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board 2Generex Biotechnology Appoints Mark Fletcher as Interim President and CEO, and John P. Barratt as Chairman of the Board 3
(Date:7/2/2015)... DUBLIN , June 25, 2015 ... the addition of the "Next Generation Biometrics Market ... to 2020" report to their offering. ... $24.4 Billion by 2020, at a CAGR of 17.9% ... is the leading application for the market. Safran ...
(Date:6/26/2015)... SPRINGVILLE, Utah , June 26, 2015 ATL ... assemblies and devices with specialties in single use solutions, headquartered ... acquisition of MedConx, Inc. (a California ... , and San Jose, Costa Rica ). ... Costa Rica with ATL Technology,s existing ...
(Date:6/24/2015)... , June 24, 2015 This report provides ... the next six years. It contains an analysis of ... along with their impact from the short, medium, and ... discusses the industry, market, and technology trends that currently, ... need of concerned authorities to efficiently manage the increasing ...
Breaking Biology News(10 mins):Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 2Next Generation Biometrics Market 2015 - Global Forecast to 2020 with Safran, NEC, 3M Cogent, Fujitsu & Suprema Dominating the $24 Billion Market 3ATL Technology Announces Acquisition of MedConx, Inc. and Expanded Global Footprint 2Automatic Identification System Market by Class, by Platform, by Application and by Geography - Global Forecasts & Analysis to 2014 - 2020 2
... In January 2012, the United States Department of Agriculture ... lunches more nutritious, which included requiring schools to increase ... fruit or vegetable with their purchased lunch. However, children ... a new study scheduled for publication in The ...
... the western Pacific Ocean may be losing their last ... to a paper published today in the scientific journal ... Researchers from the State University of Papua ... and World Wildlife Fund Indonesia released a report today ...
... The COMBACTE (Combatting Bacterial Resistance in Europe) project, resulting ... IMI, is one of the projects that is part ... It is the result of the initial association between ... run respectively by Marc Bonten of the University of ...
Cached Biology News:Libertarian paternalism and school lunches: Guiding healthier behavior while preserving choices 2New study shows continued decline in the last remaining stronghold for leatherback sea turtles 2COMBACTE: A new step in the fight against resistance to antibiotics 2COMBACTE: A new step in the fight against resistance to antibiotics 3
... Human IgM Assay Kit to address the ... assay for Human IgM that eliminates the ... a simple mix-and-read assay that allows the ... ng/ml in approximately 30 minutes. The Pierce ...
... Lipid adsorption and clarification reagent; ... the purification of antibodies, proteins, nucleic ... has negligible cross-reactivity, and improves downstream ... a solid-phase, non-ionic adsorbent supplied as ...
... bovine protein-free alternative to StabilCoat Immunoassay Stabilizer. ... contains non-toxic chemicals in a PBS buffer ... and does not contain a preservative. ... and other biomolecules that are absorbed or ...
... lyophilization stabilizer is designed to stabilize ... for long-term storage. There are ... It is a convenient 10 ... and is superior to other traditional ...
Biology Products: